What is Nintedanib?

Category: Prescription Drugs

Most popular types: Ofev IPF Phase III Nintedanib (BIBF1120)

false

Nintedanib is a medication used for the treatment of idiopathic pulmonary fibrosis (IPF). Nintedanib is a kinase inhibitor that blocks multiple pathways that may be involved in the scarring of lung tissue.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 20
Moderate 41
Mild 69
None 40

Commonly reported side effects and conditions associated with Nintedanib

Side effect Patients
Diarrhea 76
Nausea 39
Decreased appetite 38
Abdominal pain 33
Indigestion 31
Vomiting 26

Show all 44 reported side effects

Dosages

Based on patients currently taking Nintedanib

Dosage Patients
150 mg twice daily 40
100 mg twice daily 11
150 mg daily 3
300 mg daily 3
200 mg daily 1
200 mg twice daily 1
300 mg twice daily 1

Why patients stopped taking Nintedanib

Multiple reasons could be selected

Reason Patients
Side effects too severe 20
Doctor's advice 11
Other 7
Did not seem to work 3
Expense 1
See all 31 patients who've stopped taking Nintedanib

Duration

Currently taking Nintedanib

Duration Patients
1 - 6 months 4
6 months - 1 year 4
1 - 2 years 14
2 - 5 years 39

Stopped taking Nintedanib

Duration Patients
Less than 1 month 5
1 - 6 months 17
6 months - 1 year 7
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 148
Usually 17
Sometimes 0
Never taken as prescribed 5
Burden
Burden Evaluations
Very hard to take 4
Somewhat hard to take 12
A little hard to take 34
Not at all hard to take 120
Cost per month
Cost per month Evaluations
$200+ 13
$100-199 1
$50-99 6
$25-49 20
< $25 56
Not specified 74

What people switch to and from

Patients started taking Nintedanib after stopping:

Treatment Patients
Pirfenidone (Esbriet) 25
Azathioprine (Imuran) 2
Clindamycin (Clindamycin PH 1% Gel) 1
Doxycycline (Doxylin) 1
Fluticasone (Flovent HFA) 1

Show all 9 treatments patients report switching from

Patients stopped taking Nintedanib and switched to:

Treatment Patients
Pirfenidone (Esbriet) 12
Azathioprine (Imuran) 1
Mycophenolate mofetil (CellCept) 1
Oxygen therapy 1
Last updated:
There are no evaluations for Nintedanib.